Literature DB >> 21159146

V559A and N822I double KIT mutant melanoma with predictable response to imatinib?

Kevin McDonnell, Bryan Betz, Douglas Fullen, Christopher D Lao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21159146     DOI： 10.1111/j.1755-148X.2010.00822.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  3 in total

1.  Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report.

Authors:  Samia Arifi; El Mehdi Tazi; Omar El Mesbahi; Hassan Errihani
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).

Authors:  Su Jin Lee; Tae Min Kim; Yu Jung Kim; Kee-Taek Jang; Hyo Jin Lee; Soon Nam Lee; Mi Sun Ahn; In Gyu Hwang; Suee Lee; Moon-Hee Lee; Jeeyun Lee
Journal:  Oncologist       Date:  2015-09-30

3.  Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.

Authors:  Yara Abdou; Ankita Kapoor; Lamya Hamad; Marc S Ernstoff
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.